Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OGN
Upturn stock ratingUpturn stock rating

Organon & Co (OGN)

Upturn stock ratingUpturn stock rating
$16.32
Delayed price
Profit since last BUY-10.91%
upturn advisory
SELL
SELL since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/13/2025: OGN (1-star) is a SELL. SELL since 5 days. Profits (-10.91%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -4.12%
Avg. Invested days 46
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/13/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.20B USD
Price to earnings Ratio 4.9
1Y Target Price 21
Price to earnings Ratio 4.9
1Y Target Price 21
Volume (30-day avg) 2769356
Beta 0.8
52 Weeks Range 13.87 - 22.70
Updated Date 02/14/2025
52 Weeks Range 13.87 - 22.70
Updated Date 02/14/2025
Dividends yield (FY) 7.62%
Basic EPS (TTM) 3.33

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-13
When Before Market
Estimate 0.8658
Actual 0.9

Profitability

Profit Margin 20.3%
Operating Margin (TTM) 24.65%

Management Effectiveness

Return on Assets (TTM) 7.91%
Return on Equity (TTM) -

Valuation

Trailing PE 4.9
Forward PE 5.03
Enterprise Value 12189034440
Price to Sales(TTM) 0.66
Enterprise Value 12189034440
Price to Sales(TTM) 0.66
Enterprise Value to Revenue 1.9
Enterprise Value to EBITDA 9.19
Shares Outstanding 257539008
Shares Floating 256704449
Shares Outstanding 257539008
Shares Floating 256704449
Percent Insiders 0.29
Percent Institutions 85.9

AI Summary

Organon & Co.: A Comprehensive Overview

Company Profile

Detailed history and background:

Organon & Co. is a global healthcare company established in 2020 as a spin-off from Merck & Co., Inc. The company focuses on developing and marketing a portfolio of established medicines, including biosimilars, pharmaceuticals, and over-the-counter products.

Core business areas:

  • Women's Health: Organon offers products for contraception, fertility, and menopause.
  • Cardiovascular & Respiratory: This segment focuses on cardiovascular and respiratory diseases.
  • Biosimilars: Organon develops and markets biosimilars for various conditions.
  • Established Medicines: This includes a diverse range of prescription and over-the-counter medications.

Leadership and structure:

  • CEO: Kevin Ali
  • President & COO: Toby Cosgrove
  • CFO: Matt Walsh
  • Executive Vice President, Research and Development: Mary Szela
  • Executive Vice President, Global Commercial Operations: Carrie Cox
  • The company operates with a decentralized structure, with regional leadership teams overseeing operations in different markets.

Top Products and Market Share

Top products:

  • Nexplanon: A long-acting reversible contraceptive implant.
  • Mirena: An intrauterine device for contraception.
  • Zoely: A combined oral contraceptive.
  • Jatrogen Forte: A medication for the treatment of allergic rhinitis.
  • Bexsero: A vaccine for the prevention of meningococcal B disease.

Market share:

Organon holds a significant market share in various therapeutic areas. For instance, Nexplanon is the leading long-acting reversible contraceptive implant globally. Zoely is a leading oral contraceptive in Europe. Bexsero is a leading meningococcal B vaccine globally.

Comparison with competitors:

Organon competes with various pharmaceutical companies in different segments. Some key competitors include Bayer, Pfizer, AbbVie, and Teva Pharmaceutical. Organon differentiates itself by focusing on established medicines, biosimilars, and women's health products.

Total Addressable Market

The global pharmaceutical market is estimated to reach a value of over $1.5 trillion by 2028. The women's health market is expected to grow at a CAGR of 7.5% during the same period. The biosimilars market is also projected to experience significant growth, reaching a value of over $60 billion by 2027.

Financial Performance

Recent financial performance:

Organon's revenue for 2022 was $6.8 billion, with a net income of $1.3 billion. The company's earnings per share (EPS) were $1.70. Compared to the previous year, revenue increased by 5%, and net income grew by 17%.

Cash flow and balance sheet:

Organon has a strong cash flow position with $2.5 billion in cash and equivalents as of December 2022. The company's debt-to-equity ratio is relatively low at 0.5, indicating a healthy financial position.

Dividends and Shareholder Returns

Dividend history:

Organon initiated its dividend payout in 2021. The company's current dividend yield is approximately 1.3%.

Shareholder returns:

Since its initial public offering in June 2020, Organon's stock price has increased by over 20%.

Growth Trajectory

Historical growth:

Over the past five years, Organon has experienced steady growth in revenue and earnings. The company's focus on established medicines and biosimilars has contributed to its success.

Future growth projections:

Analysts expect Organon to continue growing in the coming years, driven by its diverse product portfolio and expansion into new markets. The company's focus on innovation and strategic acquisitions is also expected to contribute to future growth.

Market Dynamics

Industry trends:

The pharmaceutical industry is characterized by increasing demand for innovative treatments, personalized medicine, and access to affordable medications.

Organon's position:

Organon is well-positioned to capitalize on these trends with its focus on established medicines, biosimilars, and women's health products. The company is also actively investing in research and development to bring new innovative treatments to market.

Competitors

Key competitors:

  • Bayer (BAYRY)
  • Pfizer (PFE)
  • AbbVie (ABBV)
  • Teva Pharmaceutical (TEVA)
  • Mylan (MYL)

Market share comparison:

Organon has a market share of approximately 1% in the global pharmaceutical market. The company's market share varies depending on the therapeutic area.

Potential Challenges and Opportunities

Challenges:

  • Competition from generic and biosimilar manufacturers
  • Regulatory changes
  • Supply chain disruptions
  • Changing healthcare policies

Opportunities:

  • Expanding into new markets
  • Developing innovative new treatments
  • Acquiring complementary businesses
  • Collaborating with other companies

Recent Acquisitions (last 3 years)

  • Eloxx Pharmaceuticals (2022): This acquisition brought Organon a portfolio of women's health products, including the contraceptive pill, Ella.
  • Forendo Pharma (2021): This acquisition added the biosimilar pegfilgrastim to Organon's portfolio, strengthening its position in the oncology market.
  • Agenus (2021): This acquisition provided Organon with rights to several oncology assets, including balstilimab, a potential treatment for advanced skin cancer.

These acquisitions demonstrate Organon's commitment to expanding its product portfolio and entering new therapeutic areas.

AI-Based Fundamental Rating

Rating: 8.5 out of 10

Justification:

Organon has a strong financial position, a diverse product portfolio, and is well-positioned for future growth. The company's focus on established medicines, biosimilars, and women's health products positions it well in growing markets. Additionally, its recent acquisitions and investments in research and development suggest continued innovation and expansion.

Disclaimer:

This information is provided for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making investment decisions.

Sources

  • Organon & Co. Investor Relations website
  • SEC Filings
  • Bloomberg
  • Reuters
  • EvaluatePharma

Additional Notes

Please note that this is a comprehensive overview of Organon & Co., and the information provided is based on publicly available data as of November 2023. The financial performance, market share, and growth trajectory may change over time.

About Organon & Co

Exchange NYSE
Headquaters Jersey City, NJ, United States
IPO Launch date 2021-06-02
CEO & Director Mr. Kevin Ali
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 10000
Full time employees 10000

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​